Glimepiride + metformin: Indication, Dosage, Side Effect, Precaution

Generic Medicine Info Full Generic Medicine Info

Dosage/Direction for Use Contraindications Special Precautions Adverse Reactions Drug Interactions Action CIMS Class ATC Classification

This information is not country-specific. Please refer to the India prescribing information.

Generic Medicine Info

Contraindications

Hypersensitivity diabetic ketoacidosis (DKA); renal dysfunction; CHF (CHF), patients undergoing radiological studies; acute or chronic metabolic acidosis. Pregnancy, lactation.

Special Precautions

Renal and hepatic impairment. Avoid alcohol consumption. Hypoglycaemic episodes.

Adverse Reactions

Diarrhoea, vomiting, metallic taste, rash, isolated transaminase elevations, cholestatic jaundice, allergic skin reactions, photosensitivity reactions, leukopaenia, agranulocytosis, thrombocytopaenia, haemolytic anaemia, aplastic anaemia, pancytopaenia, blurred vision.
Potentially Fatal: Lactic acidosis.

Drug Interactions

Concomitant admin with propranolol increases Cmax, AUC, and T_1/2 of glimepiride. Aspirin increases the mean AUC of glimepiride. Furosemide increases the C_max of metformin.

CIMS Class

Antidiabetic Agents

ATC Classification

A10BA02 - metformin ; Belongs to the class of biguanides. Used in the treatment of diabetes.
A10BB12 - glimepiride ; Belongs to the class of sulfonylureas. Used in the treatment of diabetes.

Disclaimer: This information is independently developed by CIMS based on glimepiride + metformin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 CIMS. All rights reserved. Powered by CIMSAsia.com